Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Open Label, Single Arm, Extension Trial to Examine Long-term Safety of Iclepertin Once Daily in Patients With Schizophrenia Who Have Completed Previous Iclepertin Phase III Trials (CONNEX-X)

NCT05211947 is registered in ClinicalTrials.gov with Boehringer Ingelheim as lead sponsor.

NCT NCT05211947
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05211947 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Open Label, Single Arm, Extension Trial to Examine Long-term Safety of Iclepertin Once Daily in Patients With Schizophrenia Who Have Completed Previous Iclepertin Phase III Trials (CONNEX-X)
Lead sponsor
Boehringer Ingelheim
Phase
Phase 3
Overall status
Terminated
Start date
March 21, 2022
Completion date
March 18, 2025
Enrollment
1,356 (actual)
Sites
303

Conditions

As the registry lists them; a condition with its own page is linked.

schizophrenia